1. Home
  2. NXL vs BRTX Comparison

NXL vs BRTX Comparison

Compare NXL & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.81

Market Cap

18.6M

Sector

Health Care

ML Signal

HOLD

Logo BioRestorative Therapies Inc. (NV)

BRTX

BioRestorative Therapies Inc. (NV)

HOLD

Current Price

$1.19

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXL
BRTX
Founded
2010
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Managed Health Care
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.6M
9.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NXL
BRTX
Price
$0.81
$1.19
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
117.5K
35.5K
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$156,931.00
$383,400.00
Revenue This Year
$38.28
$112.14
Revenue Next Year
$185.71
$139.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.70
52 Week Low
$0.70
$0.98
52 Week High
$3.87
$2.55

Technical Indicators

Market Signals
Indicator
NXL
BRTX
Relative Strength Index (RSI) 32.96 50.62
Support Level $0.79 $1.04
Resistance Level $1.01 $1.16
Average True Range (ATR) 0.05 0.08
MACD -0.01 0.02
Stochastic Oscillator 13.29 78.26

Price Performance

Historical Comparison
NXL
BRTX

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

About BRTX BioRestorative Therapies Inc. (NV)

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Share on Social Networks: